Beximco Pharmaceuticals Limited

DSE:BXPHARMA Stock Report

Market Cap: ৳30.1b

Beximco Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Beximco Pharmaceuticals has a total shareholder equity of BDT50.4B and total debt of BDT6.9B, which brings its debt-to-equity ratio to 13.8%. Its total assets and total liabilities are BDT70.2B and BDT19.8B respectively. Beximco Pharmaceuticals's EBIT is BDT7.8B making its interest coverage ratio 6.9. It has cash and short-term investments of BDT1.7B.

Key information

13.8%

Debt to equity ratio

৳6.95b

Debt

Interest coverage ratio6.9x
Cash৳1.73b
Equity৳50.41b
Total liabilities৳19.81b
Total assets৳70.22b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: BXPHARMA's short term assets (BDT21.8B) exceed its short term liabilities (BDT12.1B).

Long Term Liabilities: BXPHARMA's short term assets (BDT21.8B) exceed its long term liabilities (BDT7.7B).


Debt to Equity History and Analysis

Debt Level: BXPHARMA's net debt to equity ratio (10.3%) is considered satisfactory.

Reducing Debt: BXPHARMA's debt to equity ratio has reduced from 36.7% to 13.8% over the past 5 years.

Debt Coverage: BXPHARMA's debt is well covered by operating cash flow (120.5%).

Interest Coverage: BXPHARMA's interest payments on its debt are well covered by EBIT (6.9x coverage).


Balance Sheet


Discover healthy companies